Cite
HARVARD Citation
Muranushi, H. et al. (2022). Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial. Hematology. 27 (1), pp. 239-248. [Online].